by Geeta Shroff, MD Dr. Shroff is Director of Nutech Mediworld in New Delhi, India. Innov Clin Neurosci. 2017;14(3–4):12–16. Funding: No funding was received for the preparation of this article.
by Chad Gwaltney, PhD; James C Mundt, PhD; John H. Greist, MD; Jean Paty, PhD; and Brian Tiplady, PhD Dr. Gwaltney is with Gwaltney Consulting, Westerly, Rhode Island (with ERT
by Katie T.B. Touma, PharmD, BCPP, BCPS; Allysa M. Zoucha, PharmD, BCPP; and Jonathan R. Scarff, MD Drs. Blissit and Zoucha are with William Jennings Bryan Dorn VA Medical Center,
by Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital, in Hiroshima, Japan, and Dr. Nagamine is with
by Ann L. McNary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Innov Clin Neurosci. 2017;14(3–4)41–44. This ongoing column is dedicated to providing information to
Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms
by Jagannadha Avasarala, MD, PhD Dr. Avasarala is with the Department of Internal Medicine, Division of Neurology, Greenville Health System, Neuroscience Associates, in Greenville, South Carolina. Innov Clin Neurosci. 2017;14(3–4):38–40.
Read More